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Regulation of Blood Vessel versus Lymphatic Vessel
Growth in the Cornea
Eui-Sang Chung,1,2,3,4 Daniel R. Saban,1,2,4 Sunil K. Chauhan,1,2 and Reza Dana1,2,5
PURPOSE. In the present study, the authors developed novel
models to stimulate blood vessel formation (hemangiogenesis)
versus lymphatic vessel formation (lymphangiogenesis) in the
cornea.
METHODS. Micropellets loaded with high-dose (80 ng) or low-
dose (12.5 ng) basic fibroblast growth factor (bFGF) were
placed in BALB/c corneas. Angiogenic responses were ana-
lyzed by immunohistochemistry to quantify blood neovessels
(BVs) and lymphatic neovessels (LVs) to 3 weeks after implan-
tation. Areas covered by BV and LV were calculated and ex-
pressed as a percentage of the total corneal area (percentage
BV and percentage LV). Hemangiogenesis (HA) and lym-
phangiogenesis (LA) were also assessed after antibody block-
ade of VEGFR-2 or VEGFR-3
RESULTS. Although high-dose bFGF stimulation induced a more
potent angiogenic response, the relative LV (RLV percentage
LV/percentage BV  100) was nearly identical with high- and
low-doses of bFGF. Delayed LA responses induced 3 weeks
after implantation of high-dose bFGF resulted in a lymphatic
vessel-dominant phenotype. Interestingly, the blockade of
VEGFR-2 significantly suppressed BV and LV. However, the
blockade of VEGFR-3 inhibited only LV (P  0.0002) without
concurrent inhibition of BV (P  0.79), thereby resulting in a
blood vessel-dominant phenotype
CONCLUSIONS. An HA-dominant corneal phenotype can be ob-
tained in BALB/c mice 2 weeks after implantation of an 80-ng
bFGF micropellet with VEGFR-3 blockade. Alternatively, an
LA-dominant corneal phenotype can be obtained 3 weeks after
implantation of an 80-ng bFGF micropellet without supplemen-
tary modulating agents. These models will be useful in evalu-
ating the differential contribution of BV and LV to a variety of
corneal abnormalities, including transplant rejection, wound
healing and microbial keratitis. (Invest Ophthalmol Vis Sci.
2009;50:1613–1618) DOI:10.1167/iovs.08-2212
Stratification of clinical risk factors for corneal graft rejectionhas identified recipient bed vascularity as the principal
cause of earlier and more fulminant rejection episodes1–3 be-
cause blood vasculature is the conduit by which immune cells
gain entry to the corneal matrix.4 However, lymphatic neoves-
sels in the cornea may be as, or even more, important because
these vessels provide alloantigen-bearing antigen-presenting
cells effective access to regional lymph nodes. However, be-
cause the presence of lymphatic vessels is undetectable by
clinical slit lamp examination, unlike blood neovessels, the
importance of lymphangiogenesis in graft rejection may be
underappreciated. Previous reports have demonstrated that
suppression of the eye-lymphatic axis abrogates the induction
of alloimmunity and potently augments graft survival.5,6 How-
ever, precise delineation of the differential regulation of he-
mangiogenesis (HA) and lymphangiogenesis (LA), the manner
by which these distinct processes regulate transplant immu-
nity, and a large number of diverse corneal inflammatory con-
ditions have not been addressed.
To this end, the study of HA and LA individually is particu-
larly difficult because pathologic conditions stimulate angio-
genic and inflammatory responses concurrently, leading to
coincident HA and LA. With the use of corneal suture place-
ment to induce inflammation-associated neovascularization,
however, Bock et al.7 were able to selectively inhibit corneal
lymphangiogenesis through systemic blockade of VEGFR3, and
Dietrich et al.8 achieved a similar effect through the systemic
blockade of 5 integrin. Alternatively, intrastromal micropellet
implantation with low-dose FGF has been shown to selectively
stimulate lymphangiogenesis and has been further shown to be
amplified through the administration of exogenous soluble
VEGFR-1.9,10 Thus, though FGF was initially characterized as
the sole inducer of HA, its role in inducing LA has also been
appreciated.11–13
In the present study, we developed two distinct angiogenic
models, an HA-dominant phenotype, characterized by the pres-
ence of blood neovessels (BVs) and a relative absence of lymph
neovessels (LVs) and an LA-dominant phenotype, characterized
by the presence of LV with a paucity of BV. We used the
micropocket assay to this end because it is considered a spe-
cific method to induce corneal neovascularization. Further-
more, micropellets were impregnated with high-dose (80 ng)
basic fibroblast growth factor (bFGF). As described herein, this
dose is important in stimulating a robust angiogenic response.
This is relevant to the considerable interest that has recently
emerged in further understanding the strong angiogenic re-
sponses associated with microbial keratitis in addition to high-
risk corneal transplantation.14–18 Consequently, the develop-
ment of in vivo models that can robustly, yet differentially,
induce HA compared with LA dominance would be consider-
ably useful in studying the disparate roles of blood and lym-
phatic vessels in a number of corneal immune-mediated and
inflammatory abnormalities.
MATERIALS AND METHODS
Animals
Male 6- to 8-week-old BALB/c mice were used in all experiments.
Animals were anesthetized intraperitoneally (120 mg/kg ketamine and
20mg/kg xylazine per body weight) before any surgery and were
treated in accordance with the ARVO Statement for the Use of Animals
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in Ophthalmic and Vision Research. Experiments described herein
were conducted under institutional animal care and use committee
approval.
Pellet Implantation
High-dose (80 ng) and low-dose (12.5 ng) bFGF (a gift from BRB
Preclinical Repository, National Cancer Institute) pellets were pre-
pared as previously described.18 An initial half-thickness linear incision
was made at the center of cornea with a disposable 30° microknife
(FST; Applied Biosystems, Foster City, CA). A lamellar pocket incision
was then made parallel to the corneal plane with a von Graefe knife
(FST; Applied Biosystems) and advanced to the temporal limbus at a
lateral canthal area. The pellets were positioned into the pocket 1 mm
apart from the limbal vascular arcade, and tetracycline ophthalmic
ointment was applied to the eye after pellet implantation.
Slit Lamp Biomicroscopic Examination
Eyes were examined by slit lamp biomicroscopy on postoperative days
7 and 14. Photographs were taken through retroillumination, whereby
pupils were first dilated (2.5% phenylephrine hydrochloride and 1%
tropicamide ophthalmic solution) before slit lamp photomicrographs
were taken.
Immunohistochemistry and Morphometry
of HA and LA
After taking photographs under the slit lamp, five mice per group were
killed 1, 2, and 3 weeks after implantation, and freshly enucleated eyes
were prepared into corneal flat mounts. Immunohistochemical stain-
ing was performed with FITC-conjugated CD31/PECAM-1 (rat-anti–
mouse antibody; 1:100; Santa Cruz Biotechnology, Santa Cruz, CA).
Staining against LYVE-1 (lymphatic endothelium-specific hyaluronic
acid receptor; goat-anti–rabbit antibody; 1:400; Abcam, Cambridge,
MA) was also performed with purified antibody followed by rhodam-
ine-conjugated secondary antibody. To quantify the level of BV forma-
tion (CD31high/LYVE-1) or LV formation (CD31low/LYVE-1high), low-
magnification (2) micrographs were captured, and the area covered
by BVs and LVs was calculated (NIH ImageJ software 1.34; developed
by Wayne Rasband, National Institutes of Health, Bethesda, MD; avail-
able at http://rsb.info.nih.gov/ij/index.html) and expressed as a per-
centage of the total corneal area (%BV and %LV). In addition, to specify
the level of LA in relation to total angiogenic response, the relative LV
(RLV) was calculated using this equation: RLV  %LV/%BV  100.
Real-Time PCR
The suture model was used by placement of intrastromal sutures
(11–0) with three interrupted figure-of-eight knots on the circum-
ference of the paracentral cornea for 1 versus 3 weeks, or normal
cornea as a control. RNA was subsequently isolated from recipient
corneas (RNeasy Micro Kit; Qiagen, Valencia, CA) and reverse tran-
scribed (Superscript III Kit; Invitrogen Life Technologies, Carlsbad,
CA). Real-time PCR was performed (TaqMan Universal PCR MasterMix;
Applied Biosystems, Foster City, CA), and primers were prefor-
mulated for VEGF-A (assay ID Mm00437304_ml), VEGF-C (assay ID
Mm00437313_ml), VEGF-D (assay ID Mm00438965_ml), VEGFR-3
(assay ID Mm00433337_ml) and GAPDH (assay ID Mm99999915_gl)
(Applied Biosystems). Results were derived from the comparative
threshold cycle method and normalized by GAPDH as an internal
control. Values obtained from normal corneas were then used to
calculate relative mRNA expression for experimental corneas.
VEGF Receptor Neutralization with
Blocking Antibodies
Monoclonal antibodies were used to block VEGFR-2 (DC101) or mu-
rine VEGFR-3 (mF4–31C1).19–23 Both blocking antibodies were sup-
plied by Bronislaw Pytowski (Imclone Systems Inc., New York, NY)
based on our signed material transfer agreement. One milligram (0.5
mL) of anti–mouse VEGFR-2 or anti–mouse VEGFR-3, or both, was
injected through the intraperitoneal route at days 0 (before pellet
implantation), 2, 4, 7, 10, and 13 to neutralize the function of each
receptor. The same amount of rat immunoglobulin (IgG) was injected
as an isotype control in control mice. Mice were grouped based on the
treatment received (n  5 per group).
Statistical Analysis
The values of BV, LV, and RLV were statistically compared between
different growth factor dosages (12.5 and 80 ng) and time points
(weeks 1, 2, and 3) with the use of ANOVA. The inhibitory effects of
specific VEGFR-2 or -3 blockades on HA and LA were evaluated by
comparing percentage BV or percentage LV of each treatment group
with those of the nontreated control group with the two-tailed Stu-
dent’s t-test. P  0.05 was considered statistically significant.
RESULTS
Biomicroscopic Comparison of Low- versus
High-Dose bFGF Stimulation on
Corneal Hemangiogenesis
Because disparate doses of bFGF stimulation may induce dif-
ferent levels of blood vessel ingrowth, we first examined this
potential effect on BALB/c corneas through biomicroscopic slit
lamp examination. Either low-dose (12.5 ng) or high-dose (80
ng) bFGF-containing micropellets were implanted into the cor-
neal stroma and examined as late as 3 weeks after implantation
to evaluate the inducibility and sustainability of the stimulated
hemangiogenesis. We found the response to be substantially
stronger with high-dose bFGF, as measured by slit lamp exam-
ination (Fig. 1A), which was particularly obvious at 1 week
after implantation. This time point also coincided with peak
hemangiogenesis after high-dose bFGF stimulation because
subsequent time points showed substantial regression of
neovessels (Fig. 1B). This regression was also indicated by a
change in the angiogenic pattern: week 1 revealed a robust
ringlike pattern of BVs, whereas weeks 2 and 3 resembled a
more localized and restricted wedge-shape pattern (Fig. 1B).
Development of an LA-Dominant
Corneal Phenotype
Corneas implanted with low- or high-dose bFGF pellets were
prepared into flat mounts and evaluated until 3 weeks after
implantation through immunofluorescence microscopy. LVs
were identified as CD31low/LYVE-1high, and BVs were identi-
fied as CD31high/LYVE-1 vessels (Fig. 2A). The percentage LV,
percentage BV, and RLV were calculated as described in Mate-
rials and Methods. Interestingly, though the RLV values ob-
tained were relatively identical between the two doses, both
the percentage LV and the percentage BV observed after low-
dose bFGF stimulation were significantly lower (P  0.0007
and 0.0014, respectively) than those observed with high-dose
bFGF mice (Fig. 2B). In addition, further evaluation of high-
dose bFGF mice indicated that maximal percentage LV was
observed 3 weeks after implantation, whereas concurrent per-
centage BV was relatively marginal (Figs. 3A, 3B). Therefore,
these data indicate that an LA-dominant corneal phenotype can
be obtained in BALB/c mice 3 weeks after implantation of an
80-ng bFGF micropellet.
To verify these observations indicating that the LA re-
sponses can increase while concomitant HA responses subside
over time, we compared mRNA levels of various genes whose
expressions are important in eliciting HA or LA (Fig. 3C).
Recipient corneas were therefore collected at 1 versus 3 weeks
after stimulation of neovascularization, and real time-PCR was
used to quantify mRNA levels of VEGF-A, VEGF-C, VEGF-D, and
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VEGFR-3. We found that whereas levels of VEGF-A subsided
modestly, a near twofold increase (or greater) was observed in
the levels of VEGF-C, VEGF-D, and VEGFR-3 (P 0.04) at week
3 compared with week 1.
Development of an HA-Dominant
Corneal Phenotype
To develop an HA-dominant corneal phenotype, we focused
on high-dose bFGF stimulation because low-dose stimulation
induced a far less robust angiogenic response. To further facil-
itate the development of an HA-dominant phenotype, we also
tested whether specific VEGFR-2 or VEGFR-3 antibody block-
ade could minimize the RLV and thereby promote an HA-
dominant phenotype (Fig. 4). Although their mechanisms of
stimulating HA are different, the ligation of either VEGFR-2 or
VEGFR-3 may be important in eliciting the HA response.9,11
Thus, BALB/c mice were implanted with 80-ng bFGF micropel-
lets and treated systemically with anti-VEGFR-2 or VEGFR-3.
Control mice were obtained by implanting an 80-ng bFGF
micropellet without VEGFR antibody blockade. VEGFR-2
blockade inhibited percentage BV and percentage LV substan-
tially compared with nontreated controls (Fig. 4B). However,
VEGFR-3 blockade only led to a significant inhibition of LV
relative to the nontreated controls (P  0.0002), whereas
concurrent percentage BV was statistically similar (P 0.79) to
the percentage of nontreated controls (Fig. 4b).
In the aggregate, these data indicate that an HA-dominant
corneal phenotype can be obtained in BALB/c mice 2 weeks
after implantation of an 80-ng bFGF micropellet and VEGFR-3
blockade. Alternatively, an LA-dominant corneal phenotype
can be obtained in BALB/c mice 3 weeks after implantation of
an 80-ng bFGF micropellet, without supplementary modulating
agents (Table 1).
DISCUSSION
In this study, we have developed novel angiogenic models
for investigation of the role of BVs versus LVs in corneal
immunity. The first model is a hemangiogenic-dominant
model whereby blood neovessels are present with minimal
presence of lymphatic neovessels. In contrast, the lymph-
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FIGURE 1. Biomicroscopic examination of corneal hemangiogenesis
induced by low- versus high-dose bFGF stimulation. (A) Stimulation of
robust hemangiogenesis requires implantation of a high-dose (80 ng)
bFGF-impregnated micropellet. BALB/c mice (n  5) were implanted
with either a low-dose (12.5 ng) or a high-dose micropellet into the
corneal stroma and compared 1 week after implantation by slit lamp
examination. (B) Stimulation with high-dose bFGF peaked at week 1
after implantation. BALB/c mice (n 5) were implanted with a high-dose
(80 ng) micropellet and followed up until 3 weeks after implantation.
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FIGURE 2. Analysis of corneal he-
mangiogenesis and lymphangiogen-
esis induced by low- versus high-dose
bFGF stimulation. (A) Representative
micrographs demonstrate the impor-
tance of high-dose bFGF stimulation
in eliciting a hemangiogenic and lym-
phangiogenic response. Corneal flat
mounts of BALB/c mice stimulated
with low- or high-dose bFGF were
prepared 1 week after implantation
and immunostained against CD31
(green) and LYVE-1 (red). (B) Per-
centage area of host cornea covered
by BV (CD31high/LYVE-1, green) or
LV (CD31low/LYVE-1high, red) was
calculated (n  5 per group). Rela-
tive lymphatic vessel values (RLV, %),
which equal LV/BV  100, were also
calculated. Student’s t-test was used
for statistical analysis (*P  0.0007;
**P  0.0014).
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angiogenic-dominant model is characterized by robust lym-
phatic neovessels whereas the presence of blood neovessels
is marginal. Chang et al.9 demonstrated that bFGF can selec-
tively induce lymphatic vessels using a 12.5-ng bFGF micro-
pellet implanted into the corneal stroma. However, in the
present study, we observed that angiogenic stimulation with
a 12.5-ng bFGF micropellet relative to 80 ng stimulation was
too weak to be considered high risk from an immunoinflam-
matory standpoint and not reflective of the significant angiogenic
responses seen in clinical settings.
It has been shown that hemangiogenic vessels are initi-
ated earlier and can persist longer than lymphangiogenic
vessels, implicating that preexisting blood vascular bed may
be necessary to guide lymphangiogenesis.19,20 Recent stud-
ies, including our current work, have indicated that this is
not always the case. Lymphangiogenesis, for example, can
be initiated before or even in the absence of hemangiogen-
esis.9 Here we also demonstrate, using high-dose bFGF (80
ng) micropellets, an LA-dominant phenotype in the cornea,
which is attributed to the persistence, or even increase, in
lymphangiogenesis in spite of a regression in hemangiogen-
esis. We found that the mean RLV value was 213 at week 3
compared with 45 at week 1 after implantation (approxi-
mately 4.7-fold difference), and percentage LV was nearly
twofold higher than percentage BV at 3 weeks after trans-
plantation. Moreover, this was corroborated by quantitative
(real-time) PCR measuring mRNA levels of relevant VEGF
species. Increases in VEGF-C, VEGF-D, and VEGFR-3 (but not
VEGF-A) were observed at 3 weeks rather than 1 week after
stimulation.
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FIGURE 3. Development of an LA-
dominant corneal phenotype. (A)
Representative micrographs demon-
strate the LA-dominant phenotype
observed 3 weeks after high-dose
bFGF stimulation. (B) Corneal flat
mounts immunostained against CD31
(green) and LYVE-1 (red) were quan-
tified for percentage LV, percentage
BV, and RLV (red) as late as 3 weeks
after implantation (n  5 per time
point). (C) Corneas, collected at 1
rather than 3 weeks after stimulation
(n  3 corneas per group), were
assayed through real-time PCR to
quantify mRNA levels of HA- or LA-
associated genes, including VEGF-A,
VEGF-C, VEGF-D, and VEGFR-3. The
experiment was repeated twice with
similar results, and the Student’s t-
test was used for statistical analysis
(*P  0.04).
FIGURE 4. Development of an HA-
dominant recipient model. (A) Sys-
temic VEGFR-3 blockade leads to an
HA-dominant phenotype. Represen-
tative images of biomicroscopic and
immunohistochemical micrographs
demonstrate the effect of VEGFR-2
versus VEGFR-3 blockade (or no
treatment) at 2 weeks after high-dose
bFGF stimulation. Corneal flat mounts
were immunostained against CD31
(green) and LYVE-1 (red). (B) Per-
centage area of cornea covered by
BV (CD31high/LYVE-1, green) or LV
(CD31low/LYVE-1high, red) was calcu-
lated (n  5 per group). The Mann-
Whitney U test was used to deter-
mine statistical significance (**P 
0.01; *P  0.05).
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We did not anticipate this delayed nature in the LA
response to bFGF, which became apparent only by 2 and 3
weeks after implantation. However, this observation may be
explained because bFGF cannot directly ligate VEGFR-3 to
stimulate LA. Hence, activation of the VEGFR-3 receptor
would rely on downstream activation, possibly by de novo
secretion of VEGF-C or VEGF-D from inflammatory cells.9,11
Indeed, macrophages are rich sources of prolymphatic fac-
tors.21 Thus our data most likely highlight the importance of
LA stimulation through an indirect means.
The development of an HA-dominant phenotype required
the addition of modulating factors after bFGF stimulation
(unlike in the previous LA-dominant phenotype), and we
tested whether this could be achieved through systemic
blockade of VEGFR-2 or VEGFR-3. We did this because
though bFGF can directly stimulate HA, it can also lead to
inflammation-associated activation of VEGFR-2 and VEGFR-
3.16,24,25 Indeed, we observed that VEGFR-2 blockade inhib-
ited HA and LA levels similarly after bFGF stimulation be-
cause the reductions of percentage BV and percentage LV
compared with nontreated controls were nearly identical
and thereby not suitable in the creation of an HA-dominant
phenotype. In contrast, VEGFR-3 blockade selectively inhib-
ited LA while HA remained intact and uninhibited because
the reduction of percentage LV compared with nontreated
controls was nearly 10-fold, indicating a suitable method for
creating an HA-dominant phenotype.
In conclusion, we have demonstrated that an HA-domi-
nant corneal phenotype can be obtained in BALB/c mice 2
weeks after implantation with an 80-ng bFGF micropellet
and VEGFR-3 blockade. Alternatively, an LA-dominant cor-
neal phenotype can be obtained in BALB/c mice 3 weeks
after implantation of an 80-ng bFGF micropellet, without
supplementary modulating agents. Future investigations us-
ing these models will help discern the respective and differ-
ential roles of these two angiogenic compartments in high-
risk corneal transplantation and other immune corneal
disorders.
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